SCHEMBL30133146

SCHEMBL30133146

C[C@H]1Cc2sc(NC(=O)[C@H](C)NC(=O)OCc3ccccc3)c(C(=O)c3c(F)cccc3F)c2C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.43
CTSK P43235 2/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
KIF11 P52732 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
RORC P51449 1/20 0.37
CYP3A4 P08684 2/20 0.37
TSHR P16473 2/20 0.37
TP53 P04637 1/20 0.37
PREP P48147 2/20 0.37
MME P08473 1/20 0.37
ECE1 P42892 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30133082 1.00 CYP1A2 (0.43) CYP1A2CTSKMEN1KMT2AKDM4E
SCHEMBL30133127 1.00 CYP1A2 (0.43) CYP1A2CTSKMEN1KMT2AKDM4E
SCHEMBL30133184 0.85 PDE4B (0.42) MEN1KMT2AKDM4EALDH1A1LMNA
SCHEMBL30133105 0.84 CYP1A2 (0.44) CYP1A2CTSKCYP3A4TSHRPREP
SCHEMBL29207742 0.81 CYP1A2 (0.41) CYP1A2CTSKMEN1KMT2ALMNA
SCHEMBL29207744 0.81 CYP1A2 (0.41) CYP1A2CTSKMEN1KMT2ALMNA
SCHEMBL29207775 0.80 CYP1A2 (0.44) CYP1A2CTSKMEN1KMT2AKDM4E
SCHEMBL30876753 0.80 CYP1A2 (0.42) CYP1A2CTSKMEN1KMT2AKDM4E
SCHEMBL30133147 0.79 PDE4B (0.46) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL30133180 0.79 PDE4B (0.46) MEN1KMT2AKDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240190889-A1 NEW CYCLOPENTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 POSITIVE ALLOSTERIC MODULATORS HOFFMANN-LA ROCHE INC. (US) 2024-06-13 US disclosed
EP-4380940-A1 NEW CYCLOPENTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM F. Hoffmann-La Roche AG (CH) 2024-06-12 EP disclosed
WO-2023012130-A1 NEW CYCLOPENTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM F. HOFFMANN-LA ROCHE AG (CH) 2023-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190889-A1 NEW CYCLOPENTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 POSITIVE ALLOSTERIC MODULATORS GABRA1, GABRA5, GABRB1 CYP1A2 753/4885CTSK 3109/4885MEN1 3621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.